PDE9 inhibitor heart failure trials hit a dose problem
October 11, 2026
AI summary — for doctors, generated from the source snippet
Why it matters
Two phase II placebo-controlled trials of a PDE9 inhibitor in heart failure were suspected of having tested the wrong dose, sending the programme back to the drawing board.
Clinical relevance
This is a development setback for the drug class, so no clinical use is expected until dosing is re-examined.
Who should care
This is an AI-generated summary of the source's own press release/snippet, not a clinical recommendation. Verify against the original source before acting on it.
Original source summary
(MedPage Today) -- PHOENIX -- The development of a PDE9 inhibitor for heart failure hit a major roadblock, as two phase II placebo-controlled trials were suspected of having tested the wrong dose. In both heart failure with reduced ejection...
Verbatim from MedPage Today's own feed — "And It's Back to the Drawing Board for PDE9 Inhibition in Heart Failure"
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
More medical news